GSK shrugs off generic threat to Advair; U.K. again rejects Roche's Tarceva for maintenance;

@FiercePharma: Can we foot the bill for pricey prostate-cancer meds? Article | Follow @FiercePharma

> Potential generic rivals to GlaxoSmithKline's $8 billion-a-year Advair treatment for asthma and smoker's cough can hope to capture only "a very small fraction" of its sales, the British drugmaker's research chief said. Report

> MannKind said it will pay $16 million to a unit of Merck & Co to settle a dispute related to the termination of an insulin supply agreement. Report

> Britain's health cost watchdog has again rejected Roche's Tarceva pill for long-term use in lung cancer patients because it is too costly for the benefit it offers. Report

> Diabetic patients with a vision-robbing eye condition who were treated with Roche's (ROG.VX) Lucentis had significant and sustained vision improvement compared with those who received a placebo, according to new trial data. Report

> Amgen (AMGN) sold $3 billion of bonds in the largest debt sale this month as borrowing costs for investment-grade companies fall to about the lowest this year. Report

> Pfizer is threatening U.K. pharmacies with legal action if they supply Teva Pharmaceutical's knockoff versions of the cholesterol drug Lipitor before a court fight between the companies is resolved. Report

> Danish drugmaker Novo Nordisk (NOVOb.CO) is applying for U.S. approval for use of its diabetes drug Victoza in combination with long-acting insulins. Report

> The generic drug metformin is a cost-effective way to help prevent Type 2 diabetes in people at high risk of developing the chronic condition, according to a new economic analysis. Report

> Merck has broadened its North American distribution and logistics deal with UPS to distribute pharmaceuticals internationally. Report

Biotech News

@FierceBiotech: Competition gets fierce for innovative science. Report | Follow @FierceBiotech 

@JohnCFierce: Chatted with Ian Tomlinson, worldwide business czar for GSK. Can't say I learned much new, though oncology, inflammation are a hot deal source. | Follow @JohnCFierce

Drug Delivery News

> Red-blooded delivery device gets by body's defenses. Report

> MEMS implant could target diabetic retinopathy. Article

> Nebraska nanoscientist returns to Mother Russia with $4.5M grant. Story

> Digna to use Flamel's drug-delivery technologies in three products. Article

> Pop goes the nanotube for targeted drug delivery. Item

> Defense Department interested in Impel's BBB-busting device. Report

Medical Device News

> Allegro enters agreement with schools for lung cancer testing platform. Story

> Live from BIO 2011: Polybatics looks to improve diagnostics through beads. Report

> InfraReDx raises $24.1M from equity offering. Article

> Medtronic's Infuse targeted in scientific journal. News

> Medtronic introduces mobile app for use with cardiac devices. Report

And Finally... Barry J. Marshall, the Australian scientist who won a Nobel Prize for identifying a cancer-causing stomach bacterium, plans to start a trial next year using the bug in a drinkable flu vaccine. Report